SEATTLE — In this Healio Video Perspective from the ARVO meeting, Jennifer I. Lim, MD, discusses anti-VEGF therapy for the treatment of proliferative sickle cell retinopathy.
Lim and colleagues with the Anti-VEGF Versus Prompt Laser for Proliferative Sickle Cell Retinopathy (ALPS) group investigated 37 patients who received anti-VEGF therapy for proliferative sickle cell retinopathy, considered stage 3 or stage 4, along with concurrent or as-needed laser. The majority of patients had improvements in their visual acuity and anatomic outcomes.
“In patients with stage 3, almost every patient had improvement of two or more lines of vision or stability of vision, and so we were pleased to see this,” Lim said. “This study will now inform our ALPS group prospective study in which we will compare anti-VEGF to laser treatment for patients with stage 3 or stage 4 disease.”
Sources/Disclosures
Collapse
Lim JI, et al. Anti-VEGF therapy for stages 3 and stage 4 proliferative sickle cell retinopathy results in improved anatomic and visual outcomes. Presented at: Association for Research in Vision and Ophthalmology meeting; May 5-9, 2024; Seattle.
Disclosures:
Lim reports receiving research grants from and consulting for Genentech/Roche and Regeneron.